Xeris Biopharma Holdings, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plan
On June 12, 2025, Marla Persky, the Chairperson of the Company’s board of directors, adopted a Rule 10b5-1 trading arrangement providing for the sale from time to time of an aggregate of up to 31,000 shares of the Company's common stock. Ms. Persky’s Rule 10b5-1 trading arrangement was adopted in order to sell-to-cover a number of shares of the Company’s common stock to satisfy tax withholding obligations in connection with the vesting of Ms. Persky's restricted stock units. The trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c). The duration of the trading arrangement is until June 30, 2026, subject to the earlier termination as provided in the plan.
During the six months ended June 30, 2025, no other directors or officers adopted, materially modified, orterminated any contract, instruction, or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any non-Rule 10b5-1 trading arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.